Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.67 USD | -1.57% |
|
-3.60% | -7.02% |
Projected Income Statement: Revolution Medicines, Inc.
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 50.04 | 42.98 | 29.39 | 35.38 | 11.58 | 0.3462 | 1.385 | 4.39 |
Change | - | -14.1% | -31.62% | 20.38% | -67.27% | -97.01% | 300.01% | 217.06% |
EBITDA 1 | - | -108.1 | -184.9 | -253.2 | -481.1 | -660.8 | -771 | -809.4 |
Change | - | - | 71.09% | 36.94% | 89.97% | -37.36% | -16.67% | -4.99% |
EBIT 1 | -54.12 | -110.7 | -188 | -258.3 | -487.2 | -663.6 | -766.9 | -811.3 |
Change | - | 104.54% | 69.84% | 37.38% | 88.63% | -36.21% | -15.57% | -5.79% |
Interest Paid 1 | -0.106 | -0.071 | - | - | - | -2.506 | - | - |
Earnings before Tax (EBT) 1 | -52.04 | -108.5 | -187.1 | -249.1 | -439.9 | -577.4 | -714 | -777.1 |
Change | - | 108.56% | 72.39% | 33.16% | 76.57% | -31.25% | -23.67% | -8.84% |
Net income 1 | -61.9 | -110.4 | -187.1 | -248.7 | -436.4 | -581.2 | -711 | -781.4 |
Change | - | 78.31% | 69.5% | 32.93% | 75.46% | -33.19% | -22.32% | -9.91% |
Announcement Date | 30/03/20 | 02/03/21 | 28/02/22 | 27/02/23 | 26/02/24 | - | - | - |
Forecast Balance Sheet: Revolution Medicines, Inc.
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | -123 | - | -577 | -645 | -1,853 | -1,786 | -1,149 | -717 |
Change | - | - | - | -211.79% | -387.29% | -196.39% | -164.33% | -162.4% |
Announcement Date | 30/03/20 | 02/03/21 | 28/02/22 | 27/02/23 | 26/02/24 | - | - | - |
Cash Flow Forecast: Revolution Medicines, Inc.
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
CAPEX 1 | 2.589 | 2.933 | 6.528 | 10.82 | 7.729 | 11.39 | 10.88 | 12.29 |
Change | - | 13.29% | 122.57% | 65.69% | -28.54% | 47.39% | -4.47% | 12.95% |
Free Cash Flow (FCF) 1 | -52.2 | -103 | -153.7 | -235.2 | -358.3 | -565.5 | -657.9 | -658.4 |
Change | - | 97.29% | 49.24% | 53.03% | 52.33% | 57.82% | 16.34% | 0.09% |
Announcement Date | 30/03/20 | 02/03/21 | 28/02/22 | 27/02/23 | 26/02/24 | - | - | - |
Forecast Financial Ratios: Revolution Medicines, Inc.
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
EBITDA Margin (%) | - | -251.46% | -629.21% | -715.77% | -4,154.36% | -190,894.89% | -55,680.36% | -18,437.95% |
EBIT Margin (%) | -108.15% | -257.54% | -639.7% | -730.01% | -4,207.12% | -191,706.1% | -55,389.9% | -18,480.64% |
EBT Margin (%) | -103.99% | -252.5% | -636.58% | -704.14% | -3,798.71% | -166,792.17% | -51,568.52% | -17,701.73% |
Net margin (%) | -123.7% | -256.8% | -636.58% | -702.95% | -3,768.28% | -167,908.68% | -51,347.27% | -17,799.77% |
FCF margin (%) | -104.32% | -239.62% | -522.99% | -664.83% | -3,094.14% | -163,361.26% | -47,513.04% | -14,998.55% |
FCF / Net Income (%) | 84.33% | 93.31% | 82.16% | 94.58% | 82.11% | 97.29% | 92.53% | 84.26% |
Profitability | ||||||||
ROA | -31.65% | -28.02% | -28.66% | -32.11% | -30.38% | -25.2% | -33.3% | -51.5% |
ROE | - | -68.54% | -34.74% | -38.63% | -34.76% | -29.57% | -39.29% | -63.12% |
Financial Health | ||||||||
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Debt / Free cash flow | - | - | - | - | - | - | - | - |
Capital Intensity | ||||||||
CAPEX / Current Assets (%) | 5.17% | 6.82% | 22.21% | 30.57% | 66.74% | 3,290.93% | 785.95% | 279.98% |
CAPEX / EBITDA (%) | - | -2.71% | -3.53% | -4.27% | -1.61% | -1.72% | -1.41% | -1.52% |
CAPEX / FCF (%) | -4.96% | -2.85% | -4.25% | -4.6% | -2.16% | -2.01% | -1.65% | -1.87% |
Items per share | ||||||||
Cash flow per share 1 | - | - | - | - | -3.098 | -3.468 | -3.623 | - |
Change | - | - | - | - | - | 11.95% | 4.44% | - |
Dividend per Share 1 | - | - | - | - | - | - | - | - |
Change | - | - | - | - | - | - | - | - |
Book Value Per Share 1 | -2.586 | 8.65 | 8.127 | 7.578 | 16.14 | 12.27 | 8.149 | 5.35 |
Change | - | -434.51% | -6.05% | -6.75% | 112.97% | -23.96% | -33.6% | -34.35% |
EPS 1 | -1.049 | -2.01 | -2.57 | -3.08 | -3.86 | -3.479 | -4.016 | -4.253 |
Change | - | 91.61% | 27.86% | 19.84% | 25.32% | -9.87% | 15.43% | 5.91% |
Nbr of stocks (in thousands) | - | 66,380 | 73,687 | 88,791 | 164,565 | 184,795 | 184,795 | 184,795 |
Announcement Date | 30/03/20 | 02/03/21 | 28/02/22 | 27/02/23 | 26/02/24 | - | - | - |
2024 * | 2025 * | |
---|---|---|
P/E ratio | -11.7x | -10.1x |
PBR | 3.31x | 4.99x |
EV / Sales | 16,552x | 4,598x |
Yield | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- RVMD Stock
- Financials Revolution Medicines, Inc.

MarketScreener is also available in this country: United States.
Switch edition